Clin Cancer Res 2021 Jul 4;27(13):3584-3594. Epub 2021 May 4.
The University of Texas MD Anderson Cancer Center, Houston, Texas.
Purpose: Inhibition of histone deacetylase 6 (HDAC6) is predicted to deliver both direct antitumor activity and modulation of the antitumor immune response. This study describes the development of a novel HDAC6 inhibitor.
Patients And Methods: KA2507 was characterized in HDAC biochemical and cellular target engagement assays and in preclinical efficacy models of melanoma and colorectal cancer. Read More